"This observational study provides important real-world insights into statin usage patterns and suggests that the choice of statin may have a significant effect on whether a patient remains on their prescribed medication," said Rochelle Chaiken, vice president of Pfizer's global cardiovascular and metabolic medical team, in a statement.

The company's stock was down 1.4% at $17.50. Katherine Hunt kh

COPYRIGHT

Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.

MMMM

However Pfizer notified the FDA that the safety information contained in a companion banner complementing the video was not displayed due to a technical error at CNN.com. In addition, Pfizer also announced that it withdrew all internet-based video ads featuring Viva Viagra! spots, which require a companion banner with the appropriate risk information to simultaneously appear with the video.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

According to a release by Pfzer News, the Court's April 24 order was in response to a request by one of the individual defendants in the case to subpoena the letters.

"Government approval is at the heart of these cases. Pfizer has said all along that both the Kano State and Federal governments were fully aware and approved of the Trovan clinical study. Now, the Nigerian people can confirm that with their own eyes," said Pfizer spokesman Chris Loder. One of the subpoenaed documents is a March 20, 1996, letter from Nigeria's National Agency for Food and Drug Administration Control (NAFDAC) - the Nigerian authority responsible for approving clinical studies - to the U.S. Food and Drug Administration (FDA), providing approval for Trovan to be used as part of a clinical study. The letter reads in part:" We have been supplied with adequate information about the drug and its proposed investigational use by the sponsor. The drug will be used for investigational use only. The drug may be legally used by the investigators in Nigeria." Years later, in response to an inquiry by a Federal Government committee investigating the matter, NAFDAC again confirmed that it had approved the Trovan clinical study.

"Available evidence show that in 1996, NAFDAC legally granted permit to Pfizer Plc. to import the un-registered drug, Oral Trovan, into Nigeria, for the purpose of clinical trial investigations," says the January 5, 2001, letter.

Other letters between Pfizer and federal authorities show: the Federal Government's invitation to Pfizer to come to Nigeria; an exchange between the Federal Ministries of Health and Finance seeking to facilitate the entry of Pfizer medicines and medical supplies into Nigeria via the ports; and the authorization to import Pfizer medicines and other medical supplies duty free.

The letters between Pfizer and Kano State authorities also address various issues, including the state's authorization for Pfizer doctors to treat patients. "Approval is also hereby given for your staff to participate in treating patients at our hospitals," reads a letter from Kano's Ministry of Health to Pfizer Products Plc. dated April 2, 1996.

Pfizer stands by its clinical study, which was conducted with the full knowledge and approval of the Nigerian government, consent of the participants and consistent with Nigerian laws.

"We could not be more pleased to have an executive with Peter's background, experience and vision join the Noven team," said Wayne P. Yetter, Noven's Chairman. "Noven has a proud and successful history in the development and commercialization of transdermal products. Last year, in order to diversify its prospects and significantly increase its longer-term growth rate, the company embarked on an ambitious strategy to transform itself into a broader-based specialty pharmaceutical company. Just as he led the pharmaceutical operations of one of the largest and most established companies in the world, we are confident that Peter is the ideal executive to lead Noven's transformation, strategy and growth in the years ahead."

"I am honored to be asked to lead Noven and join its board," said Brandt, "and excited about the chance to help the company evolve from primarily a transdermal drug delivery company to a high-growth specialty pharmaceutical company. Noven has an impressive array of assets, including outstanding transdermal patch technologies, the highly successful Novogyne joint venture, and a specialty pharmaceutical unit with a significant pipeline. I look forward to working with the team to refine the strategies that will capitalize on these assets, to successfully execute on those strategies, and to build substantial value for Noven shareholders."

As CEO, Brandt succeeds Interim CEO Jeffrey F. Eisenberg, who will remain with Noven as Executive Vice President. The board appointed Eisenberg to the interim leadership position following the January 2008 retirement of Robert C. Strauss. At that time, Noven's board separated the offices of Chairman and CEO, appointing then lead independent director Wayne Yetter as Noven's non-executive Chairman. In line with good corporate governance practices, the offices will remain separated, and Yetter will continue to serve as Chairman.

"The board thanks Jeff for leading Noven forward strategically and operationally over the past several months," said Yetter. "He confirmed his outstanding leadership and importance to the organization by taking charge at a challenging time, and we look forward to his continued contributions to the company."

About Noven

Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven's commercialized transdermal products utilize its proprietary DOT Matrix(R) drug delivery technology and include Vivelle-Dot(R) (estradiol transdermal system), the most prescribed estrogen patch in the U.S., and Daytrana(TM) (methylphenidate transdermal system), the first and only patch approved for the treatment of ADHD. Oral products currently offered through the Noven marketing and sales infrastructure consist of Pexeva(R) (paroxetine mesylate) and Lithobid(R) (lithium carbonate). Developmental products in psychiatry consist of Stavzor(TM) (delayed release valproic acid capsule), Lithium QD (once-daily lithium carbonate), and Stavzor(TM) ER (extended release valproic acid capsule). The development program in women's health consists of Mesafem(TM) (low-dose paroxetine mesylate), a non-hormonal product scheduled to enter Phase 3 clinical trials for vasomotor symptoms (hot flashes). See www.noven.com for additional information.

Safe Harbor Statement under the Private Litigation Reform Act of 1995

Except for historical information contained herein, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve substantial risks and uncertainties. Statements that are not historical facts, including statements that are preceded by, followed by, or that include, the words "believes," "anticipates," "plans," "expects" or similar expressions and statements are forward-looking statements. Noven's estimated or anticipated future results, product performance or other non-historical facts are forward-looking and reflect Noven's current perspective on existing trends and information. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the current expectations of Noven and are subject to a number of risks and uncertainties that are subject to change based on factors that are, in many instances, beyond Noven's control.

These forward-looking statements include the risk that, for any number of reasons, Noven may not achieve its longer-term growth objectives and other goals. For additional information regarding these and other risks associated with Noven's business, readers should refer to Noven's Annual Report on Form 10-K as well as other reports filed from time to time with the Securities and Exchange Commission. Unless required by law, Noven undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

SOURCE: Noven Pharmaceuticals, Inc.

Noven Pharmaceuticals, Inc., Miami
Joseph C. Jones, Vice President - Corporate Affairs
305-253-1916